37
Participants
Start Date
September 11, 2014
Primary Completion Date
March 15, 2018
Study Completion Date
March 15, 2018
Single intratumoral injection of DNX-2401
"In the randomized group, following brain tumor biopsy and histological confirmation of recurrent glioblastoma/gliosarcoma, a single injection of DNX-2401 was administered directly into the brain tumor with or without subsequent interferon gamma (IFN-γ)~No additional subjects will be randomized. A single intratumoral dose of DNX-2401 will be delivered by cannula."
Interferon-gamma
In the randomized group, a single injection of DNX-2401 was followed by interferon gamma (IFN-γ). No additional subjects will be randomized or receive IFN-γ following DNX-2401
Moffitt Cancer Center, Tampa
The Ohio State University, Columbus
Baylor University: Charles A. Sammons Cancer Center, Dallas
UT MD Anderson Cancer Center, Houston
Lead Sponsor
DNAtrix, Inc.
INDUSTRY